Cholinesterase Enzymes Inhibitors from the Leaves of Rauvolfia Reflexa and Their Molecular Docking Study

被引:25
作者
Fadaeinasab, Mehran [2 ]
Hadi, A. Hamid A. [1 ,2 ]
Kia, Yalda [3 ]
Basiri, Alireza [4 ]
Murugaiyah, Vikneswaran [4 ]
机构
[1] Univ Malaya, Dept Chem, Fac Sci, Kuala Lumpur 50603, Malaysia
[2] Univ Malaya, Dept Chem, Fac Sci, Kuala Lumpur 50603, Malaysia
[3] Univ Sains Malaysia, Sch Chem Sci, George Town 11800, Malaysia
[4] Univ Sains Malaysia, Sch Pharmaceut Sci, George Town 11800, Malaysia
关键词
Apocynaceae; Rauvolfia reflexa; acetylcholinesterase; butyrylcholinesterase; molecular docking; ACETYLCHOLINESTERASE;
D O I
10.3390/molecules18043779
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Plants of the Apocynaceae family have been traditionally used in the treatment of age-related brain disorders. Rauvolfia reflexa, a member of the family, has been used as an antidote for poisons and to treat malaria. The dichloromethane, ethanol and methanol extracts from the leaves of Rauvolfia reflexa showed potential acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitory activities, with IC50 values in the 8.49 to 52.23 g/mL range. Further cholinesterase inhibitory-guided isolation of these extracts afforded four bioactive compounds, namely: (E)-3-(3,4,5-trimethoxyphenyl)acrylic acid (1), (E)-methyl 3-(4-hydroxy-3,5-dimethoxyphenyl)acrylate (2), 17-methoxycarbonyl-14-heptadecaenyl-4-hydroxy-3-methoxycinnamate (3) and 1,2,3,4-tetrahydro-1-oxo-beta-carboline (4). The isolated compounds showed moderate cholinesterase inhibitory activity compared to the reference standard, physostigmine. Compounds 1 and 2 showed the highest inhibitory activity against AChE (IC50 = 60.17 mu M) and BChE (IC50 = 61.72 mu M), respectively. Despite having similar molecular weight, compounds 1 and 2 were structurally different according to their chemical substitution patterns, leading to their different enzyme inhibition selectivity. Compound 2 was more selective against BChE, whereas compound 1 was a selective inhibitor of AChE. Molecular docking revealed that both compounds 1 and 2 were inserted, but not deeply into the active site of the cholinesterase enzymes.
引用
收藏
页码:3779 / 3788
页数:10
相关论文
共 14 条
[2]   Piperamides and their derivatives as potential anti-trypanosomal agents [J].
Cotinguiba, Fernando ;
Regasini, Luis Octavio ;
Bolzani, Vanderlan da Silva ;
Debonsi, Hosana Maria ;
Passerini, Gabriela Duo ;
Barretto Cicarelli, Regina Maria ;
Kato, Massuo Jorge ;
Furlan, Maysa .
MEDICINAL CHEMISTRY RESEARCH, 2009, 18 (09) :703-711
[3]   Chemical constituents from leaves of Palicourea coriacea (Rubiaceae) [J].
da Silva, Virginia Claudia ;
de Carvalho, Mario Geraldo ;
Alves, Aline Nogueira .
JOURNAL OF NATURAL MEDICINES, 2008, 62 (03) :356-357
[4]  
Fadaei M., 2011, MALAYS J SCI, V30, P154
[5]   β-Carboline alkaloids from the leaves of Trigonostemon lii YT Chang [J].
Li, Shi-Fei ;
Zhang, Yu ;
Li, Yan ;
Li, Xin-Rao ;
Kong, Ling-Mei ;
Tan, Cheng-Jian ;
Li, Shun-Lin ;
Di, Ying-Tong ;
He, Hong-Ping ;
Hao, Xiao-Jiang .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (06) :2296-2299
[6]   Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer's disease [J].
Martinez, A ;
Castro, A .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2006, 15 (01) :1-12
[7]   Update on the Pharmacological Treatment of Alzheimer's Disease [J].
Massoud, Fadi ;
Gauthier, Serge .
CURRENT NEUROPHARMACOLOGY, 2010, 8 (01) :69-80
[8]   Ethnomedicine of the Kagera Region, north western Tanzania. Part 3: plants used in traditional medicine in Kikuku village, Muleba District [J].
Moshi, Mainen J. ;
Otieno, Donald F. ;
Weisheit, Anke .
JOURNAL OF ETHNOBIOLOGY AND ETHNOMEDICINE, 2012, 8
[9]   Effects per se of organic solvents in the cerebral acetylcholinesterase of rats [J].
Obregon, ADC ;
Schetinger, MRC ;
Correa, MM ;
Morsch, VM ;
da Silva, JEP ;
Martins, MAP ;
Bonacorso, HG ;
Zanatta, N .
NEUROCHEMICAL RESEARCH, 2005, 30 (03) :379-384
[10]   Acetylcholinesterase inhibitors: a patent review (2008-present) [J].
Pohanka, Miroslav .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2012, 22 (08) :871-886